TNFRSF8 and classic Hodgkin lymphoma: BV, which consists of a monoclonal antibody targeting CD30 and the anti-tubulin agent monomethyl auristatin E (MMAE), coupled via a protease-sensitive linker, was first approved by the Food and Drug Administration (FDA) in 2011 for the treatment of relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and systemic anaplastic large cell lymphoma (sALCL).